Announcement: Promising TB vaccine candidate progresses to Phase I clinical trials

The MTBVAC01 vaccine candidate, developed to protect people against tuberculosis, will start Phase I clinical trials early in 2012. This was announced by the Spanish biopharmaceutical company Biofabri. The candidate was developed by the University of Zaragoza, Spain and is part of the international portfolio of TuBerculosis Vaccine Initiative (TBVI). Tuberculosis causes almost two million deaths per year.

During a press conference Biofabri’s CEO Esteban Rodriguez explained that the first batch of the vaccine is now available for toxicity studies. After the results of these studies have been assessed by the European Medicines Agency, responsible for accrediting and authorising, the candidate will move to Phase I of clinical trials in humans. Phase I studies are conducted in small groups of healthy adults to check if the new vaccine can be given without any serious side effects or reaction and that it produces a good immune response. If the results are positive the vaccine candidate will move on to Phase II.

MTBVAC01, designed by TBVI’s research partner Carlos Martin of the University of Zaragoza, could replace the current BCG vaccine. It is the first and leading attenuated live vaccine globally. The results from the laboratory predict a firm protection against TB; this has to be proven in the coming years.

The research team, which has spent four years working on this project, aims to produce a vaccine that will be ‘universally accessible’, protecting millions of people around the world. According to the project’s scientific director Carlos Martin, the disease is becoming more resistant to antibiotics. Tuberculosis is the most important cause of death among people with HIV infection.

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...